DOE Proposes No New Standards for Fluorescent Lamp Ballasts

The U.S. Department of Energy's Energy Efficiency and Renewable Energy Office has issued a Notification of Proposed Determination (NOPD) regarding fluorescent lamp ballasts. DOE has tentatively determined that amended energy conservation standards for FLBs would not be cost-effective, and therefore proposes not to amend existing standards. The agency is seeking public comments on this determination and associated analyses through June 1, 2026.

Bundesbank Central Office Moving to New Frankfurt Location

The Deutsche Bundesbank's board has approved a decision to purchase a property in Frankfurt as its new headquarters, following a cost-effectiveness study comparing this option against renovating the current Wilhelm-Epstein-Straße location. The analysis found purchasing a property significantly more economical than continued operations at the existing site, with total investment costs estimated at 1.6 billion EUR versus 2.9 billion EUR for the current location through 2067.

German balance of payments, January 2026, €17.1B surplus

The Deutsche Bundesbank published Germany's balance of payments for January 2026, showing a current account surplus of €17.1 billion, slightly below the previous month. The goods trade surplus increased by €6.9 billion to €14.9 billion. Germany recorded net capital imports of €9.2 billion, reversing from net capital exports of €27.5 billion in December 2025.

German State Debt Rises €144bn to €2.8 Trillion in 2025

German state debt increased by €144 billion to €2.84 trillion in 2025, with the debt-to-GDP ratio rising from 62.2% to 63.5%. Federal debt (including extra budgets) grew by €107 billion, while states and municipalities added €19 billion and €25 billion respectively. Social security debt more than doubled from €3 billion to €7 billion.

BOEM S8219 Public Comment Solicitation - Offshore Energy and Mineral Management

The Bureau of Ocean Energy Management (BOEM) has published document S8219 for public review and comment via Regulations.gov under docket BOEM-2026-0298. The document pertains to BOEM's regulatory activities involving offshore energy development, marine mineral resources, or environmental review processes on the Outer Continental Shelf. Interested parties have until April 17, 2026 to submit comments on the proposed matter.

Huntington Disease Ultrasound Trial, Fujian Medical University

Fujian Medical University registered a Phase 1/2 clinical trial (NCT07513844) on ClinicalTrials.gov investigating low-intensity ultrasound as a treatment for Huntington disease. The trial will assess safety and preliminary efficacy parameters in patients with the neurodegenerative condition. ClinicalTrials.gov serves as the primary public registry for clinical research conducted under FDA oversight.

Iparomlimab tovorilimab bevacizumab mesothelioma trial

NIH registered a new Phase 2 clinical trial (NCT07514793) on ClinicalTrials.gov evaluating the combination of iparomlimab, tovorilimab, and bevacizumab for the treatment of mesothelioma. The trial is sponsored by Memorial Sloan Kettering Cancer Center and appears to be an open-label study investigating this immunotherapy combination. ClinicalTrials.gov serves as the primary registry for clinical trials conducted under FDA oversight.

KHN922 injection phase 1/2 solid tumor trial

ClinicalTrials.gov posted a new clinical trial registration for KHN922 injection, a Phase 1/2 study evaluating the treatment in patients with solid tumors. The trial is registered as NCT07514975 and includes study design details such as eligibility criteria and outcome measures. This registration fulfills requirements for publicly listing clinical trials conducted under FDA oversight.

Zhejiang University FAP CAR-DC trial, end-stage dilated cardiomyopathy

The National Library of Medicine registered a new Phase 1 clinical trial (NCT07516288) on ClinicalTrials.gov, sponsored by Zhejiang University in China. The trial evaluates FAP CAR-DC cell therapy for patients with end-stage dilated cardiomyopathy. The study appears in the ClinicalTrials.gov public registry as an informational record for transparency and public awareness.

Eisai E6742 trial for systemic lupus erythematosus

ClinicalTrials.gov has registered a new clinical trial (NCT07515014) for Eisai E6742, an investigational drug for systemic lupus erythematosus. The registry entry provides study metadata including phase, eligibility criteria, enrollment information, and participating locations. Pharmaceutical companies conducting clinical trials use this public registry to satisfy transparency requirements and make trial information accessible to the public.